Merck Nears Cidara Acquisition: Breakthrough Therapy Drug

Merck reportedly nearing deal to acquire Cidara Therapeutics, potentially valuing the biotech company above its market capitalization. The acquisition could involve upfront cash and milestone-based payments. Merck was in competition with another pharmaceutical company for Cidaras acquisition, but ultimately favored Mercks offer. The deal could be announced as early as Friday.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.